PYPD vs. LYRA, TTOO, ICAD, HSAQ, ALUR, NSPR, PDEX, NVNO, MGRM, and STIM
Should you be buying PolyPid stock or one of its competitors? The main competitors of PolyPid include Lyra Therapeutics (LYRA), T2 Biosystems (TTOO), iCAD (ICAD), Health Sciences Acquisitions Co. 2 (HSAQ), Allurion Technologies (ALUR), InspireMD (NSPR), Pro-Dex (PDEX), enVVeno Medical (NVNO), Monogram Orthopaedics (MGRM), and Neuronetics (STIM). These companies are all part of the "surgical & medical instruments" industry.
PolyPid (NASDAQ:PYPD) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, community ranking, profitability, media sentiment, earnings, risk and valuation.
PolyPid has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -4,099.82%. Lyra Therapeutics' return on equity of -77.34% beat PolyPid's return on equity.
PolyPid presently has a consensus price target of $14.00, suggesting a potential upside of 211.11%. Lyra Therapeutics has a consensus price target of $7.13, suggesting a potential upside of 2,072.26%. Given Lyra Therapeutics' higher probable upside, analysts plainly believe Lyra Therapeutics is more favorable than PolyPid.
26.5% of PolyPid shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Comparatively, 17.4% of Lyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
PolyPid has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500.
In the previous week, Lyra Therapeutics had 1 more articles in the media than PolyPid. MarketBeat recorded 3 mentions for Lyra Therapeutics and 2 mentions for PolyPid. PolyPid's average media sentiment score of 1.44 beat Lyra Therapeutics' score of -0.02 indicating that PolyPid is being referred to more favorably in the media.
PolyPid received 1 more outperform votes than Lyra Therapeutics when rated by MarketBeat users. Likewise, 74.19% of users gave PolyPid an outperform vote while only 61.11% of users gave Lyra Therapeutics an outperform vote.
PolyPid has higher earnings, but lower revenue than Lyra Therapeutics. PolyPid is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
PolyPid and Lyra Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get PolyPid News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
